Courtesy of UNC Davis Library
Coronavirus - COVID-19; Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)
Medical Letter on the CDC & FDA; Atlanta [Atlanta]10 May 2020: 942.Publisher logo. Links to publisher website, opened in a new window.
PDF
Save as PDF
Cite
Cite
Email
Print
All Options
Full text
Details
Full Text
Translate
2020 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Staff editors report on the newly launched clinical trial, NCT04357028, which has the following summary description: "Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV, The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19. We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness"
As a matter of record, on April 23, 2020, NewsRx staff editors report that the available information provided by Kasr El Aini Hospital on this trial include:
Tracking Information
Trial Identifier NCT04357028
First Submitted Date April 19, 2020
First Posted Date April 22, 2020
Results First Submitted Date Not Provided
Results First Posted Date Not Provided
Last Update Submitted Date April 19, 2020
Last Update Posted Date April 22, 2020
Primary Completion Date October 1, 2020
Start Date May 1, 2020
Current Primary Outcome Measures •COVID-19 disease incidence [ Time Frame: Time Frame: Measured over the 6 months following randomization ] -- Number of participants with asymptomatic or mild COVID-19 disease defined as fever (using self-reported questionnaire), plus at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire), plus positive SARS-Cov-2 test (PCR or serology)
Current Secondary Outcome Measures •SARS-CoV-2 pneumonia [ Time Frame: Time Frame: Measured over the 6 months following randomization ] -- Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test
•Critical care admission duration with SARS-CoV-2 [ Time Frame: Time Frame: Measured over the 6 months following randomization ] -- Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test
•Oxygen therapy with SARS-CoV-2 [ Time Frame: Time Frame: Measured over the 6 months following randomization ] -- Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test
Other Outcome Measures Not Provided
Change History
https://clinicaltrials.gov/archive/NCT04357028 - Complete list of historical revisions of study NCT04357028
I think it is highly likely that many young people in the US are somewhat protected by their MMR but that makes the College Age Group and below prime traffickers of the illness. Who knows, maybe COVID 19 is here to kill off the anti-vaxxers